Kornimate/medical-research-clean huggingface dataset:
artificial intelligence-enabled large-scale electrocardiogram feature extraction and exploring association between the extracted features and mortality, stroke or various health outcome of interest

Conditions: Health Status(Death, Stroke Etc)

Summary: * in this study, large-scale ecg data (electrocardiogram data of all patients stored in the muse system by measuring standard 12-guided ecg at severance health checkup at severance hospital from november 1, 2005 to october 31, 2022) are combined with electronic medical records, national health insurance corporation data, and national statistical office death cause data, and the artificial intelligence algorithm is used to extract ecg features to analyze the association between death, stroke, and various health conditions, and to conduct external verification or transfer learning using public databases (e.g., uk biobank data). * intended to use a web-based artificial intelligence platform to distribute computational loads generated during large-scale data processing and improve analysis accuracy and efficiency.

* all patient ids obtained from the main office are replaced by research ids (de-identified ids), so the actual id is not exposed and other personal identification information (name, resident registration number) is not collected. * research methods: 1. electrocardiogram extraction based on the criteria of subjects. 2. combined with extracted ecg data and national insurance corporation data (+ national statistical office cause of death data). 3. health out of interest (hoi) definition. includes death, stroke, etc. 4. the defined hoi can be extracted from yonsei medical center data or from national insurance service data or statistics korea's cause of death data. 5. artificial intelligence model training with electrocardiogram (and clinical information diagram if necessary) as input, utilizing supervised deep learning algorithms if there is a label and unsupervised learning algorithms if there is no label. 6. performance evaluation for supervised learning artificial intelligence models. 7. in the case of unsupervised learning artificial intelligence models, the association/correlation between extracted features and hoi or predictability/detectability analysis. 8. transfer learning can be performed by adding external verification or dielectric data to the learned model using public databases. 9. external verification can be performed using external additional data by mounting the learned model on a web-based artificial intelligence platform. 10. considering large-scale data, computing workloads can be distributed using web-based artificial intelligence platforms. 11. the analysis results can be anonymized and the analysis results can be provided to researchers through a web-based artificial intelligence platform.

Eligibility criteria:
inclusion criteria: all patients stored in the muse system after measuring a standard 12-guided electrocardiogram at severance health checkup at severance hospital from november 1, 2005 to october 31, 2022
comparison of the tolerability of two formulations of hypertonic saline in cystic fibrosis patients

Conditions: Cystic Fibrosis

Summary: the purpose of this study is to compare the tolerability and acceptability of a formulation containing hypertonic saline 7% (hs) alone and a formulation containing hs and hyaluronic acid 0.1% in a population of cystic fibrosis (cf) patients who already showed poor tolerance to hs.


Eligibility criteria:
inclusion criteria: * diagnosis of cystic fibrosis (genotyping and sweat test) * \> 8 year-old * clinically and therapeutically stable disease in the last 30 days; * forced expiratory volume in one second (fev1) ≥ 50% of predicted value; * intolerance (cough, throat irritation, saltiness) to previous administration of 5.8% hypertonic saline solution. exclusion criteria: * decrease in fev1 \>15% after first inhalation of hypertonic saline; * burkholderia cepacia infection; * infective exacerbation requiring antibiotic treatment in the 15 days preceding enrolment; * patient non compliant to standard therapy; * lung transplant; * patient unable to perform reproducible spirometry; * intolerance to β2 bronchodilators; * concurrent enrolment in other clinical trials; * plasmatic creatinine and transaminases more than twice the normal values.
active elements of digital single-session interventions

Conditions: Depression

Summary: depression is a leading cause of disability in young adults. however, access to care is limited due to structural and psychological barriers. single-session interventions (ssis) are structured programs designed to maximize the therapeutic output in one interaction between the patient and the provider or a program. project abc, a single-session intervention (ssi), has been shown to be effective in reducing depressive symptoms. project abc is based on four components-psychoeducation, testimonials, saying is believing exercises, and action planning. however, it is unclear what are the effects of the individual components. the primary aim of this study is to calculate the main effects of the candidate components-psychoeducation, testimonials + saying is believing exercises, and action planning-on patient health questionnaire-8 (phq-8) scores at 8-week follow-up. the secondary aims of this study are to: 1. calculate the main effects of the candidate components-psychoeducation, testimonials + saying is believing exercises, and action planning-on phq-8 scores at immediate post-treatment and 2-week follow-up. 2. calculate the interaction effects, if any, among the candidate components on phq-8 scores at immediate post-treatment, 2-week, and 8-week follow-up. 3. calculate the main and interaction effects of the candidate components on measures of hopelessness, autonomy, relatedness, and competence. 4. determine if the effects of the candidate components on phq-8 are mediated by measures of autonomy, relatedness, and competence. additionally, the exploratory aim of this study is to determine if common factors, like credibility of the intervention and expectations to improve, can lead to symptom change.


Eligibility criteria:
inclusion criteria: * located in the united states * baseline patient health questionnaire-8 (phq-8) score \>= 10 * able to read and write english * able to access to the internet via a computer, tablet or smartphone for the next eight weeks exclusion criteria: * participants who have participated in another related study on depression from our laboratory via the same participant recruitment platform in the past two months * participants who have submitted gibberish in open response questions

Keywords: active elements factorial trial single-session interventions depression
seroma and hematoma rates: maxigesic iv vs. ketorolac in breast cancer surgery

Conditions: Breast Cancer; Post-Operative Hematoma; Seroma as Procedural Complication; Post-Op Complication

Summary: the investigators aim to compare the incidence rates of seroma (fluid collection) and hematoma (blood clot) following breast cancer surgery between the conventional non-steroidal anti-inflammatory drug (nsaid) ketorolac and maxigesic. the investigators seek to determine the complication rates in patients receiving maxigesic post-surgery, hypothesizing that the higher dosage of ibuprofen in maxigesic compared to ketorolac will result in lower complication rates.


Eligibility criteria:
inclusion criteria: * systemic performance status 0-2 according to ecog criteria * patients with adequate renal function: serum cr 1.4 mg/dl or less * patients with adequate liver function bilirubin, ast/alt: 1.5 times or less of the upper limit of normal, alkaline phosphatase: 1.8 times or less of the upper limit of normal * patients undergoing total mastectomy with slnb or alnd (mastectomy and axillary sentinel lymph node dissection) * patients undergoing breast-conserving surgery with alnd (mastectomy and axillary dissection) * patients who voluntarily decided to participate in this study and signed a written informed consent form exclusion criteria: * patients undergoing immediate reconstruction operation * patients with drug allergies to painkillers and anti-inflammatory drugs * patients with a physical condition that would interfere with understanding and submitting the consent form
study of the effectiveness and safety of sugardown vs. placebo in type 2 diabetic subjects treated with metformin

Conditions: Type 2 Diabetes Mellitus

Summary: to assess the safety and effectiveness of two doses of sugardown in two different doses vs. placebo on serum glucose levels after meals in subjects with type 2 diabetes treated with metformin alone. there will be five visits, a screening visit, baseline visit, and 3 treatment visits. the study duration will be five weeks. subjects will all receive placebo tablets at the baseline visit, eat a standard rice meal, and then serum glucose levels will be measured in frequent intervals over four hours immediately following the meal. subjects will be randomized to one of the six treatment sequences. patients will take in an unknown order one week of placebo, one week of 4 g dose and one week of 8 g dose of sugardown immediately before breakfast, lunch and dinner meals. patients will continue their usual metformin regimen during the trial period.


Eligibility criteria:
inclusion criteria: * written informed consent prior to any trial-related activity * male or female, between 25-75 years of age * a diagnosis of type 2 diabetes for at least one year prior to screening visit * stable daily dose of metformin (up to 1.7 g daily) for at least 3 months prior to screening visit * body mass index (bmi) between 25 and 35 * hba1c between 6.5% and 9.0% * fasting blood glucose \< 180 mg/dl exclusion criteria: * clinically significant cardiovascular, peripheral vascular, cerebrovascular or renal disease * any clinical condition apart from diabetes type 2 that affects glycemic control, examples include diabetes type 1, liver disease, chronic pancreatitis, endocrine disease (e.g. pituitary, thyroid, adrenal gland disease), small or large intestine motility or absorptive disease, active infection, advanced malignant tumor or bariatric surgery * any concomitant anti-diabetic medication other than metformin, including, but not limited to, the following classes of medication: insulin, sulfonylureas, glinides, glitazones, alpha-glucosidase inhibitors, amylin agonists, dpp-4 inhibitors, and glp-1 agonists * any concomitant steroid, hormonal, anorexic or other medications that could significantly interfere with glycemic control in subjects * lactating or pregnant women, or women of child-bearing potential unable to use adequate birth control. * history or patient reported illicit drug abuse or alcoholism * participation in another clinical study one month preceding recruitment * any of the following laboratory abnormalities: ast or alt \> 1.5 times upper limit normal on liver function test, glomerular filtration rate \< 60 (ml/min/1.73 m2) on chemistry panel measured by mdrd criteria, and hemoglobin \< 10 g/dl on complete blood count
behavioral economic approaches for population-based colorectal cancer screening

Conditions: Colorectal Cancer

Summary: this is a 3-year pragmatic, randomized clinical trial among average-risk patients at diverse primary care practices who are overdue for colorectal (crc) screening. this project aims to evaluate the effect of a centralized program that includes direct outreach to patients and visit-based, clinician directed nudges facilitated by the electronic health record (ehr) with follow-up text messaging on the uptake of crc screening. the primary outcome is crc screening completion at 3 years. patient and clinician factors impacting the experience and effectiveness of the intervention will be explored through surveys and qualitative interviews.

despite effective strategies for prevention, early detection, and treatment, colorectal cancer (crc) remains the second leading cause of cancer death in the united states (us). while there have been considerable policy and system-level efforts to increase crc screening rates, uptake remains well below national goals of 80% participation. members of racial and ethnic minorities are even further behind. approaches to increase population-based screening can consider \[1\] how screening is encouraged by targeting the clinicians who typically order or recommend the procedure or the patient who completes it; and \[2\] the kind of screening offered (e.g., colonoscopy or fecal immunochemical testing \[fit\]). this project simultaneously tests interventions along both of these dimensions.

Eligibility criteria:
inclusion criteria: * patients ages 50-72 * followed by primary care with a participating penn medicine pcp listed and at least one visit in the last 2 years * not up to date on colorectal cancer screening per health maintenance (no colonoscopy in the last 10 years, stool testing in the last year, flexible sigmoidoscopy in the last 5 years, mt-sdna in the last 3 years). exclusion criteria: * personal or significant family history of crc, colonic polyps, hereditary nonpolyposis colorectal cancer syndrome, familial adenomatous polyposis syndrome, other gastrointestinal cancer, gastrointestinal bleeding, iron-deficiency anemia, or inflammatory bowel disease * history of total colectomy, dementia or metastatic cancer * currently on hospice or receiving palliative care * uninsured or self-pay patients * currently scheduled for a colonoscopy or sigmoidoscopy * active order for multitarget stool dna testing (mt-sdna) * history of paraplegia or quadriplegia * elevated chance of mortality within 3 years according to mortality risk algorithm * active order for fecal immunochemical test (fit) in the last 60 days * positive stool test (fit or mt-sdna) result in the last 5 years

Keywords: prevention cancer screening behavioral economics
study of of oxygen nebulized inhalation egcg in cancer patients with new coronary pneumonia

Conditions: Pneumonia, Interstitial; Cancer Patients

Summary: epigallocatechin-3-gallate (egcg) is a major polyphenol of green tea that possesses a wide variety of actions, such as anti-inflammatory, anti-fibrotic, pro-apoptotic, anti-tumorous, and metabolic effects via modulation of a variety of intracellular signaling cascades. in addition, preclinical studies have also emphasized the antiviral activity of epigallocatechin-3-gallate (egcg), including sars-cov-2. in previous studies, we found that egcg can prevent and cure radiation- induced normal tissue damage in tumor patients. in clinical studies, we found that egcg can prevent and treat radiation-induced acute radiation esophagitis, acute radiation skin injury, acute radiation oral mucositis with high safety. at the same time, the phase i clinical trial designed by us has confirmed the safety and efficacy of egcg in the treatment of interstitial pneumonia.

the phase ii study was conducted with a randomized, controlled, placebo dose determined by phase i. the subjects were divided into two groups (experimental group and placebo group). to observe the effectiveness of egcg, the researchers will use both clinician assessment and patient self-assessment. primary endpoint: change in imaging (chest ct) before and after treatment. secondary evaluation endpoints: 1 further evaluation of the safety of egcg. 2 the degree of symptom improvement . 3 changes in laboratory testing indicators.

Eligibility criteria:
inclusion criteria: * diagnosed malignant tumors by pathology or cytology * covid-19 with a confirmed positive polymerase chain reaction or antigen test result for sars-cov-23 * moderate-to-severe covid-19 pneumonia (defined as any radiographic evidence of pulmonary infiltrates and oxygen saturation \>94% on room air) * pulmonary function of the patient can be treated with aerosol inhalation for 7 days exclusion criteria: * current or recent progresses rapidly and may develop into a critical illness with coronavirus in a short period of time * caused by other viruses such as cytomegalovirus, as well as pneumocystis pneumonia, pulmonary edema, aspiration pneumonia and acute interstitial pneumonia * any condition including medical, emotional, psychiatric, or logistical that, in the opinion of the investigator would preclude the participant from adhering to the protocol or would increase the risk associated with study participation * known allergy or hypersensitivity to egcg

Keywords: egcg
impact of parathyroidectomy on cardiovascular calcification in dialysis-dependent patients

Conditions: Secondary Hyperparathyroidism; Chronic Kidney Disease Mineral and Bone Disorder; Vascular Calcification; Dialysis

Summary: this is a prospective cohort study aimed to evaluate change of cardiovascular calcification after parathyroidectomy in patients with end-stage renal disease on dialysis compared with control group on conservative treatment.


Eligibility criteria:
inclusion criteria: 1. age \> 18 years 2. esrd patients receiving long-term hemodialysis or peritoneal dialysis treatment 3. severe secondary hyperparathyroidism defined as ipth level \> 800 pg/ml, followed with hypercalcemia and/or hyperphosphatemia; with presence of one or more nodular or diffuse parathyroid hyperplasia confirmed with ct exclusion criteria: 1. primary hyperparathyroidosis as a cause of esrd
lamina cribrosa depth change with change in eye pressure

Conditions: Glaucoma, Open-Angle

Summary: this is a study of the compliance of the lamina cribrosa with change in eye pressure.

glaucoma patients and control subjects will have their internal eye structure (lamina cribrosa) imaged by optical coherence tomography (oct) standard images at two different eye pressures. in some participants, the eye pressure will be changed by one of two interventions, wearing goggles or having laser suturelysis

Eligibility criteria:
inclusion criteria: * persons who consent to drink water and be imaged exclusion criteria: * non-consenting persons * those who cannot be imaged

Keywords: biomarker
salivary cortisol measurements by mass spectrometry

Conditions: Endocrine Disorders

Summary: cortisol is a hormone critical for survival in times of stress. currently most measurements are done with blood samples. the hypothesis of this study is cortisol measured from saliva using mass spectrometry can be used to replace measurements by blood.

cortisol levels change depending on the time of day. salivary samples were collected from health controls at bedtime, midnight and first morning waking on two consecutive nights and salivary cortisol levels were measured using mass spectrometry. in a patients with possible endocrine disorders who were going through an adrenocortiotropin stimulation test for adrenal insufficiency, salivary cortisol was measured prior to giving cosyntropin and 30-40 minutes after cosyntropin.

Eligibility criteria:
inclusion criteria: * normal subjects * subjects with possible endocrine disorder exclusion criteria: * tracheostomy or ventilator dependent * gastrotomy tubed dependent or unable to eat/drink by mouth
culture media microdroplet geometry with different oil overlay and its effect on embryonic development.

Conditions: Embryonic Development; Infertility

Summary: a prospective randomized study included 1695 mii sibling oocytes collected from 100 patients undergoing icsi.

purpose: to determine the effect of culture media microdroplet geometry of different culture dishes and oil overlay on the pre implantation embryo development in dry incubators method: we used sibling oocytes splits between two different dishes : gps (life global, usa) and spl (life science, korea) with two different oils : light mineral oil (lm)(irvine, usa) and paraffin oil (po)(vitro life, sweden). all embryos cultured in dry incubators at the same conditions. statistical analysis done using spss version 23

Eligibility criteria:
inclusion criteria: * female age is ≤ 37 years old with ≥ 8 mii oocytes * males with normal semen parameters (who 2010). * we conducted three experiments all with siblings oocytes splits and all embryos exclusion criteria: * oocyte or sperm donation. * sever male factor. * any contradictions to undergoing in vitro fertilization or goandotropin stimulation.

Keywords: dry incubator osmolality oil overlay microdrops
pilot study of a multidisciplinary intervention in icu survivors at risk for psychological or physical morbidity

Conditions: Post-Intensive Care Syndrome; Depressive Symptoms; Anxiety; Physical Disability; Posttraumatic Stress Symptom; Critical Care, Intensive Care

Summary: pilot study of the feasibility and utility of an early, in-hospital multidisciplinary intervention in icu survivors at risk for psychological and physical problems post-icu stay

60 adult patients at two hospitals in region stockholm (karolinska university hospital and södersjukhuset) with an icu stay ≥12 hours with increased risk for psychological/physical sequelae will be invited to participate. intervention: early re-assessment and multidisciplinary follow-up, led by an icu follow-up staff (case manager, cm). the cm will support the patient and coordinate the rehabilitation efforts from icu discharge to primary care with a secondary, deepened assessment of symptoms in the ward, recapitulation and information about the time spent in the icu, followed by a multidisciplinary discussion with concerned specialists and the set-up of an individual rehabilitation plan communicated to the patient and the informal caregivers. the cm will keep track of the patient during hospital stay and ensure that there is a plan for further primary care rehabilitation after hospital discharge. the cm will contact the patient weekly to follow up on wellbeing and planned primary care activities until 12 weeks. at twelve weeks, patients will be assessed with regards to psychological symptoms (hads, ptss-14) and physical disability (bi). outcome: the primary outcome is the feasibility of the intervention. patients and informal caregivers will be invited to participate in semi-structured interviews that will deepen the knowledge about their views upon the intervention, needs and suggested measures to improve the patients' recovery. resource utilisation will be documented by the cm and feedback collected from involved icu staff and hospital clinicians. secondary outcomes are patients' level of psychological and physical problems and health-related quality of life. the results from the pilot study will inform a subsequent randomized controlled trial of an early follow-up intervention.

Eligibility criteria:
inclusion criteria: - patients admitted ≥12 hours to the icu with an increased risk for physical or psychological sequelae (assessed with the progress-icu/prepics instruments) exclusion criteria: * dementia or other major cognitive problems * structural brain or spinal cord injury * multiple limitations of medical treatment * insufficient language skills (swedish)

Keywords: post-intensive care syndrome pilot study early follow-up intervention
evaluation of long-term safety and efficacy of elx/tez/iva in cystic fibrosis participants 12 months of age and older

Conditions: Cystic Fibrosis

Summary: the purpose of the study is to evaluate the long-term safety, tolerability, efficacy, and pharmacodynamics (pd) of elexacaftor (elx)/tezacaftor (tez)/ivacaftor (iva).


Eligibility criteria:
key inclusion criteria: * completed study drug treatment in the parent study vx22-445-122 part b (nct05882357) or had study drug interruption(s) in the parent study but did not permanently discontinue study drug and completed study visits up to the last scheduled visit of the treatment period of the parent study key exclusion criteria: * history of drug intolerance in the parent study that would pose an additional risk to the participant * current participation in an investigational drug trial other than the parent study other protocol defined inclusion/exclusion criteria may apply.